STC-15

STORM’s lead product, STC-15, inhibits METTL3 and is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15 is currently being evaluated in a Phase 2 study in patients with select sarcomas.

METTL3 is an RNA-modifying enzyme involved in the regulation of cancer stem cell differentiation, a critical process in the development of sarcomas and other malignancies. In a Phase 1 monotherapy study, STC-15 demonstrated durable tumor regression across multiple sarcoma subtypes, underscoring its potential to target and reprogram progenitor cells that transform into cancer cells.